Atherosclerotic plaque development can conclude with a thrombotic acute event triggered by plaque rupture/ erosion. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor superfamily that, through its receptor, fibroblast growth factor-inducible 14 (Fn14), participates in vascular remodelling, increasing vascular inflammatory responses and atherosclerotic lesion size in ApoE knockout mice. However, the role of the TWEAK-Fn14 axis in thrombosis has not been previously investigated.
Introduction
Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor (TNF) family that binds to its receptor, fibroblast growth factor-inducible 14 (Fn14), to induce a large number of physiological and pathological processes depending on cell type and environment. TWEAK is expressed in many tissues and cells, while Fn14 is expressed at relatively low levels in normal conditions and highly regulated by cytokines 1 and growth factors. 2 -4 Several in vivo studies have revealed an increased expression of both TWEAK and Fn14 after tissue injury, 3 -7 suggesting a role of the TWEAK-Fn14 axis in both tissue injury and repair. In relation to vascular diseases, TWEAK and Fn14 are expressed in human atherosclerotic plaques. 1 TWEAK enhances vascular lesions associated with hyperlipidaemia in apolipoprotein E (ApoE) knockout mice by exacerbating secretion of pro-inflammatory cytokines and macrophage cell recruitment. 8 TWEAK and Fn14 are also implicated in several processes in vascular cells, such as proliferation and migration, 2,9 -10 and expression of adhesion molecules, 9 metalloproteinases, 11 -12 or cytokines, 1 monocyte cytotoxicity, 13 apoptosis, 14 and angiogenesis. 10 However, there is no information about the possible implication of the TWEAK -Fn14 axis for thrombosis. Plaque rupture or erosion, and subsequent thrombosis, represent the main complications of atherosclerosis that could lead to an acute cardiovascular event. Different molecules, such as plasminogen activator inhibitor1 (PAI-1) and tissue factor (TF), are responsible of haemostasis and thrombosis. 15 -16 Tissue factor is the principal initiator of the clotting cascade, while PAI-1 plays a critical role in inhibiting fibrinolysis, and thereby the activity of both molecules promotes thrombotic states and plays a crucial role in vascular diseases. 17 -18 Tissue factor is a 45 -50 kDa transmembrane glycoprotein that binds to factor VII and VIIa and forms a complex that induces the conversion of factor IX and X to IXa and Xa, respectively, leading to thrombin formation and insoluble fibrin deposition. Although there is a variety of cells that express TF, macrophages and smooth muscle cells (SMCs) are the major source of TF within atherosclerotic plaque. 19 Tissue factor is present in three cellular pools in SMCs, namely surface TF (active), encrypted TF, and intracellular TF, and it can be released from SMCs in microparticles. 20 Basal expression of TF is low in SMCs, but it could be increased by different molecules, such as the cytokines monocyte chemotactic protein-1 (MCP-1), CD40 ligand, and TNF-a or platelet-derived growth factor, angiotensin II, nitric oxide, and aggregated low-density lipoproteins. 18 In addition, the amount of TF within atherosclerotic plaque modulates its thrombogenicity.
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In contrast, PAI-1 is a member of the serpin superfamily proteinase inhibitors that inhibits plasminogen activator, urokinase-type plasminogen activator, and a-thrombin, decreasing dissolution of fibrin clots by the fibrolytic system. Plasminogen activator inhibitor 1 is present in healthy arteries, where is expressed by endothelial cells and SMCs. In atherosclerotic plaques, PAI-1 can be detected by electron microscopy in SMCs, macrophages, and extracellular areas. Expression of PAI-1 in SMCs within the fibrous cap is increased compared with SMCs located in the adjacent media or in normal arterial tissue, and its expression is increased during vascular damage. 22 In the present study, we examined the effect of TWEAK-Fn14 binding on TF and PAI-1 expression and activity in cultured human aorta vascular SMCs (hASMCs). In addition, we analysed the association of both proteins with Fn14 in human carotid atherosclerotic plaques. Furthermore, we have analysed the effect of recombinant TWEAK or anti-TWEAK monoclonal antibody (mAb) treatment on atherosclerotic plaques of hyperlipidaemic ApoE knockout mice.
Methods

Reagents
Ham's F-12, penicillin, streptomycin, and trypsin -EDTA were obtained from BioWhittaker (Verviers, Belgium). Fetal bovine serum was from Gibco (Paisley, UK). Recombinant human TWEAK was from Alexis (Plymouth Meeting, PA, USA). A blocking murine anti-TWEAK mouse mAb (clone P2D10) was generated in TWEAK 2/2 mice and cross-reacts with human TWEAK. The generation of mAb and TWEAK blocking activity was previously described. 7 This antibody and non- 
Western blot
Cells from different experimental conditions were collected and pelleted. Western blots of cellular or supernatant proteins were analysed as previously described. 23 The blots were incubated with anti-human tissue factor antibody (American Diagnostica Inc., Stamford, CT, USA) or antihuman PAI-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and rehybridated with anti-a-tubulin mAb (B-5 to 1 -2; Sigma, St. Louis, MO, USA) to confirm equal loading and transfer of proteins. Quantification was expressed as arbitrary densitometric units (ADU).
Tissue factor and PAI-1 activity assays
Activity of PAI-1 in the supernatants of cell cultures was determined using AssaySense Human PAI-1 Chromogenic Activity Assay Kit (AssayPro, St Charles, MO, USA). For TF activity determination, cells were lysed by sonication in a buffer of 50 mM Tris-HCl, 100 mM NaCl, and 0.1% Triton X-100, pH7.4. Tissue factor procoagulant activity was quantificated in cell lysates by Actichrome TF (American Diagnostica Inc., Stamford, CT, USA), according to the manufacter's instructions.
Animal model
Twenty-four ApoE knockout mice (16 weeks of age) were fed on a hyperlipidaemic diet (21.2% fat (0.15% cholesterol) + 16.7% proteins) for 10 weeks. After that, animals were randomized into four groups: mice injected i.p. with saline (control group ¼ 6), human recombinant TWEAK (10 mg/kg/day, n ¼ 6), anti-TWEAK mAb (1000 mg/kg/day, n ¼ 6), or nonspecific immunoglobulin G (IgG; 1000 mg/kg/day, n ¼ 6) daily for 9 days. The dose of TWEAK was chosen based on prior in vivo studies, 7 and the dose of anti-TWEAK mAb was chosen to be 100-fold in excess of the B. Muñoz-García et al.
TWEAK dose. Anaesthetized mice were saline perfused. The aorta was embedded in OCT and frozen for immunohistochemistry. The study was performed in accordance with the European Union normative and was approved by the ethical committee of our institution. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85 -23, revised 1996).
Patients
Twenty-six patients undergoing carotid end-arterectomy at Hospital Clínico (Madrid, Spain) with asymptomatic carotid stenosis (.70%) were included in the study (21 men and five women, 70 + 7 years old, 34% hyperlipidaemic, 26% diabetic). The region of the bifurcation of the common carotid artery was chosen. Atherosclerotic plaques were collected at the time of the surgery. Informed consent was obtained before enrolment in all cases. The study was approved by the hospital's ethics committee (Hospital Clínico, Madrid, Spain) according to the institutional and the Good Clinical Practice guidelines. The study was performed in accordance with the principles outlined in the Declaration of Helsinki, and all participants gave written informed consent.
Immunochemistry
Carotid atherosclerotic plaques were stored in paraformaldehyde for 24 h and later in ethanol until paraffin embedded. Plaques were cross-sectioned into 5-mm-thick pieces, dewaxed and rehydrated, and incubated overnight with goat anti-human TF (1:100 dilution; American Diagnostica Inc., Stamford, CT, USA), mouse antihuman PAI-1 (1:100 dilution, SC-8979; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or rabbit anti-human Fn14 (1:200 dilution; Cell Signaling Technology, Danvers, MA, USA). For colocalization studies, immunofluorescence was carried out on slides after performing immunohistochemistry for TF, PAI-1, or SMCs. Negative controls using the corresponding IgG were included to check for non-specific staining. Biotinylated secondary antibodies were applied for 1 h. Then avidin-biotin peroxidase complex (Vectastain ABC kit; Vector Laboratories, Burlingame, CA, USA) was added for 30 min. Sections were stained with 3,3'-diaminobenzidine (DAKO, Glostrup, Denmark), counterstained with haematoxylin, and mounted in Pertex.
Aortic roots were cross-sectioned into 4-mm-thick sections. Primary antibodies were rabbit anti-mouse TF (1:200 dilution; American Diagnostica Inc., Stamford, CT, USA) and rabbit anti-PAI-1(1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Donkey anti-rabbit biotin was used as secondary antibody and then ABComplex-horseradish peroxidase was added. The immunohystochemistry sections were stained with 3,3'-diaminobenzidine (DAKO, Glostrup, Denmark), counterstained with haematoxylin, and mounted in Kaisers Glyceringelatine (Merck, Nottingham, UK).
Quantification
Computer-assisted morphometric analysis with the Olympus semiautomatic image analysis system Micro Image software (version 1.0 for Windows) was performed by a pathologist who was blinded to the group of patients to which the atherosclerotic plaques belonged, as previously described. 1 Results are expressed as the per mm 2 for human plaques or per mm 2 for animal plaques.
Statistical analysis
Statistical analysis was performed using SPSS 11.0 statistical software. Results are expressed as means + SEM. Significance at the P , 0.05 level was assessed by Student's t-test for two groups of data and ANOVA for three or more groups. In vitro experiments were replicated B
Results
Association between
Fn14 expression and PAI-1 or TF content in human carotid atherosclerotic plaques.
We have previously observed that Fn14 is only expressed in injured vessel wall, 1 reflecting that its expression is related to the pathological tissue remodelling. However, TWEAK expression is observed in both healthy vessels and atherosclerotic plaques at similar levels. This suggests, therefore, that Fn14 is the regulated member of the TWEAK-Fn14 axis within vessel wall. Taking these data into account, we have analysed the possible relationship between Fn14 and PAI-1 or TF expression in atherosclerotic plaques. Fn14 colocalized with TF, PAI-1, and SMCs within atherosclerotic plaques ( Figure 1A ). In addition, Fn14, PAI-1, and TF expression in serial sections of atherosclerotic plaques revealed a highly positive linear correlation between Fn14 and TF (r ¼ 0.54; P , 0.001; Figure 1B ) or Fn14 and PAI-1 expression (r ¼ 0.70; P , 0.001; Figure 1C ). These results could indicate that the TWEAK -Fn14 axis participates in the regulation of PAI-1 and TF expression in the vascular wall.
TWEAK induces PAI-1 and TF expression in cultured hASMCs
We have studied whether TWEAK can modulate PAI-1 and TF mRNA and protein expression in cultured hASMCs. For that purpose, hASMCs were cultured in the absence or presence of TWEAK (0.1 mg/mL), and PAI-1 and TF mRNA or proteins were analysed. Real-time PCR revealed that TWEAK increased PAI-1 and TF mRNA expression in a dose-( Figure 2A ) and time-dependent manner (not shown), peaking at 18 h for PAI-1 and for TF ( Figure 2A ). Tissue factor is predominantly expressed on the cell surface where it can be active, 17 while newly synthesized PAI-1 is deposited by SMCs first in the extracellular matrix, and is later released from the extracellular matrix to conditioned medium. 24 For these reasons, we have analysed TF expression in cell lysates and PAI-1 secretion in culture supernatants. TWEAK induced TF protein expression in cultured hASMCs as well as PAI-1 content in culture medium in a dose-dependent manner ( Figure 2B ).
Fn14 is implicated in TF and PAI-1 expression induced by TWEAK
To delineate the implication of Fn14 expression in the signalling mechanism underlying TF and PAI-1 induction by TWEAK, we have analysed the effect of anti-Fn14 and anti-TWEAK blocking antibodies on PAI-1 and TF expression induced by TWEAK. Pre-incubation with blocking antibodies against TWEAK or Fn14 prevented PAI-1 and TF mRNA expression induced by TWEAK ( Figure 2C ). In addition, anti-TWEAK or anti-Fn14 blocking antibodies also diminished PAI-1 release and TF protein expression ( Figure 2D ). No effect was observed when cells were incubated with non-specific IgG ( Figure 2D) .
To further investigate the role of Fn14 in PAI-1 and TF mRNA induction by TWEAK, we analysed PAI-1 and TF mRNA expression in Fn14 siRNA-transfected hASMCs. Silencing of Fn14 completely prevented both PAI-1 and TF mRNA expression induced by TWEAK in hASMCs ( Figure 3A) . Similar results were observed when we studied TF protein expression and PAI-1 release into the culture medium ( Figure 3B ). No effect was observed when cells were incubated with control siRNA ( Figure 3B ).
Activity of PAI-1 and TF is increased in TWEAK-treated hASMCs
With the purpose to analyse whether the increment in PAI-1 and TF expression induced by TWEAK is reflected in their procoagulation functions, we analysed both TF activity in total cell extract and PAI-1 activity in supernatants of cultured hASMCs. TWEAK-treated cells showed an increase in TF activity (324 + 23 vs. 245 + 28 pM, Similar results were obtained when PAI-1 activity was analysed. TWEAK increased PAI-1 activity in hASMC culture medium (82 + 6 vs. 59 + 8 AU/mL, P , 0.05). Blocking TWEAK-Fn14 signalling by antibodies against TWEAK or Fn14 resulted in a reduction in PAI-1 activity (54 + 13 vs. 82 + 6 AU/mL, P , 0.05 and 59 + 8 vs. 82 + 6 AU/mL, P , 0.05, respectively). Treatment with Fn14 siRNA also reduced PAI-1 in hASMC culture supernatants (56 + 2 vs. 82 + 6 AU/mL, P , 0.05 and 49 + 10 vs. 82 + 6 AU/mL, P , 0.05, respectively; Figure 4 ).
TWEAK modulates PAI-1 and TF expression in atherosclerotic plaques from ApoE knockout mice
We have previously demonstrated that TWEAK injection increases inflammation and lesion size in hyperlipidaemic ApoE knockout mice. 6 Using the same animal model, we observed that animals injected with TWEAK showed an increment in PAI-1 expression in atherosclerotic plaques presented in the aortic root compared with animals injected with saline or non-specific IgG [9.3 + 3.3 (TWEAK) vs. 5.5 + 2.1 (Control), P , 0.05; or vs. 6.1 + 2.0 (IgG), P , 0.05; Figure 5 ]. In addition, mice treated with an anti-TWEAK mAb showed a reduced PAI-1 expression compared with control and non-specific IgG-injected mice [2.7 + 1.2 (Anti-TWEAK) vs. 5.5 + 2.1 (Control), P , 0.05;or vs. 6.1 + 2.0 (IgG), P , 0.05]. Concordantly, TWEAK injection increased TF expression in the aortic root of ApoE 2/2 mice compared with mice treated with saline or non-specific IgG [9.9 + 3.2 (TWEAK) vs. 5.3 + 1.5
(Control), P , 0.05; or vs. 6.0 + 2.3 (IgG), P , 0.05; Figure 5 ]. Moreover, TF expression decreased after anti-TWEAK mAb treatment compared with saline-or non-specific IgG-treated animals [2.9 + 1.4 (anti-TWEAK) vs. 5.3 + 1.5 (Control), P , 0.05; or vs. 6.0 + 2.3 (IgG), P , 0.05]. Furthermore, western blot from the whole aortas showed similar results to those observed in the aortic root ( Figure 5B ). These results suggest that endogenous TWEAK may play a role in PAI-1 and TF expression within the arterial wall in vivo.
Discussion
In the present work, we have shown that Fn14 is colocalized with both PAI-1 and TF within human carotid atherosclerotic plaques. Furthermore, TWEAK administration induces PAI-1 and TF expression in cultured hASMCs and in atherosclerotic plaques of hyperlipidaemic ApoE 2/2 mice. The involvement of endogenous TWEAK in plaque thrombogenicity was also demonstrated by reduced PAI-1 and TF expression after short-term treatment with anti-TWEAK neutralizing mAb in ApoE 2/2 mice.
TWEAK has been described as a mediator of many processes within the arterial wall. It is involved in development of atherosclerosis by inducing inflammation, apoptosis, proliferation, and angiogenesis. We and others have observed that Fn14 expression is highly regulated in vascular tissue, with its expression being very low in healthy vessels 1 -4 and increased in injured vessels, indicating that the TWEAK-Fn14 axis could be implicated in vascular remodelling. Tissue factor and PAI-1 expression are also increased in atherosclerotic plaques in comparison with normal vessels, 21, 25 and we have observed a positive association between Fn14 and PAI-1 or TF in human atherosclerotic plaques. These data could indicate that the TWEAK-Fn14 axis is implicated in the control of PAI-1 and TF within vessel walls. In this context, we have previously reported that Fn14 is expressed in both macrophages and SMCs in human atherosclerotic plaques, 1 and now we have observed that TWEAK increased the expression of both proteins in cultured hASMCs, one of the major sources of these molecules within atherosclerotic plaques. 17 -18 TWEAK, through its receptor, Fn14, increased the mRNA, protein and activity of both molecules, indicating that TWEAK mediated its effects at a transcriptional level. It is known that tissue factor gene expression by endothelial cells, SMCs and monocytes/macrophages is mediated by the activating protein-1 (AP-1) and nuclear factorkB (NF-kB). 26 Moreover, it has also been demonstrated that activation of PAI-1 expression by different factors in endothelial cells 27 and vascular smooth muscle cells 28 is mediated by interaction of NF-kB with its promoter. Several studies have revealed that TWEAK-Fn14 exerts many of its actions through NF-kB activation. 29 -30 Thus, TWEAK increases NF-kB activation in atherosclerotic plaques present in the aortic root of ApoE knockout mice and in the tubular cells of an experimental model of renal damage. 24, 31 The effect observed with TWEAK incubation in cultured hASMCs is related to the presence of its receptor, Fn14. Use of an anti-Fn14 blocking antibody or Fn14 siRNA prevented the increment observed 33 These data indicate that the effect observed after treatment with TWEAK is similar to that observed with other important pro-inflammatory stimuli.
Tissue factor and PAI-1 regulate thombus formation and might play a pivotal role in thrombotic complications after plaque rupture. Indeed, evidence is emerging that PAI-1 and TF may be involved in atherogenesis not only by eliciting thrombosis but also by direct actions on vascular remodelling and plaque progression or instability. Thus, both factors induce augmentation of neointimal formation, 34, 35 providing a fibrin scaffold for fibrous tissue deposition and inducing proliferation of vascular smooth muscle cells. 36, 37 In addition, up-regulation of TF and PAI-1 may contribute to plaque instability and risk of thrombo-embolic complications. 38 In this sense, PAI-1 and TF inhibitors have been postulated as a therapeutic strategy for prevention of vascular disease. 17,39 -40 Thereby, the inhibition of TWEAK-Fn14 signalling might contribute to attenuation of PAI-1 and TF overexpression in vessel walls, and to inhibit atherosclerosis development and thrombosis. In this context, we have observed that ApoE 2/2 mice injected with blocking antibodies against TWEAK showed a reduction in PAI-1 and TF expression in atherosclerotic plaques in comparison with control mice, demonstrating that an anti-TWEAK therapy might be useful to modulate both PAI-1 and TF expression in atherosclerotic plaques. In this regard, our studies also elucidate a novel mechanism whereby anti-TWEAK therapy may be a promising strategy to prevent and reduce the clinical severity of stroke.
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In conclusion, the present study reveals a novel role of TWEAK in vascular disease, by enhancing PAI-1 and TF expression. Although TWEAK has previously been postulated as a mediator of many of the processes involved in atherosclerosis, this is the first time that it has been related to plaque thrombogenicity. In addition, anti-TWEAK therapy could be a novel therapeutic approach to diminish procoagulant activity within atherosclerotic plaques.
